Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000798359-26-000057
- form_type
- 8-K
- ticker
- CSR
- cik
- 0000798359
- company_name
- CENTERSPACE
- filed_at
- 2026-06-01T20:30:13+00:00
- discovered_at
- 2026-06-01T20:32:00.391651+00:00
- generated_at
- 2026-06-01T20:38:43.104933+00:00
- sec_items
- ["7.01", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000798359-26-000057
- json_url
- https://secwatch.observer/filing/0000798359-26-000057.json
- markdown_url
- https://secwatch.observer/filing/0000798359-26-000057.md
- text_url
- https://secwatch.observer/filing/0000798359-26-000057.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same SEC item: 7.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
IDYA
IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma
IDEAYA Biosciences, Inc.
June 1, 2026, 4:05 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 7.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
DBX
Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program
DROPBOX, INC.
June 1, 2026, 9:06 AM ET
other_material
Items 1.01, 2.03, 7.01, 8.01, 9.01
same SEC item: 7.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
NXTC
NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027
NextCure, Inc.
June 1, 2026, 8:10 AM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 7.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
JBIO
Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK
Jade Biosciences, Inc.
June 1, 2026, 7:55 AM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 7.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
EIKN
Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel
Eikon Therapeutics, Inc.
June 1, 2026, 7:30 AM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 7.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
TRTX
TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B
TPG RE Finance Trust, Inc.
June 1, 2026, 5:23 PM ET
other_material
Items 7.01, 9.01
same SEC item: 7.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
PECE
Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M
Peace Acquisition Corp.
June 1, 2026, 5:16 PM ET
other_material
Items 3.02, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.